Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947078595> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W2947078595 abstract "e15682 Background: HCC is a common cause of mortality in the U.S. among men and women (5 th and 7 th , respectively) with overall five-year survival of ~18%. Sorafenib was the only FDA approved therapy for advanced HCC from 2007 until 2018. This study analyzes trends in the treatment and survival of advanced HCC before and after sorafenib approval. Methods: Adult patients ( > 18 years) with diagnosis of HCC treated with only chemotherapy from 2004 – 2014 were identified in NCDB database. Comparisons were made between 3 time frames: 2004 – 2007 (pre-sorafenib), 2008 – 2011 (early sorafenib) and 2012 – 2014 (late sorafenib). Patients treated with single or multi-agent chemotherapy were analyzed. Cox proportional hazards models were used for univariate and multivariable analyses. Kaplan-Meier method was used for survival analysis. Results: The NCDB contained 33,136 patients with HCC diagnosed between 2004 – 2014 and treated with chemotherapy alone. Patients were generally men (77.4%), over the age of 50 years (92.4%), with an elevated AFP at diagnosis (64.4%), and had limited co-morbidities (76.0%, Charlson/Deyo score of 0-1). The T-stages were T1 (26.3%), T2 (20.5%), T3 (25.6%), and T4 (16.2%). The number and proportion of patients treated with single agent chemotherapy increased significantly during the study period: 2,733 (45.3%) pre-sorafenib, 9,723 (72.7%) early sorafenib, and 13,502 (86.1%) late sorafenib. The proportion of all HCC patients in the NCDB receiving only chemotherapy increased from 17.2% to 26.4% to 28.3% across the 3 time frames. The survival of patients with advanced HCC treated only with chemotherapy improved significantly in the early and late sorafenib cohorts compared to the pre-sorafenib cohort (10.3 months (95% CI: 9.8-10.6) vs. 12.3 months (12.0-12.7) vs. 15.5 months (15.1-15.9), p-value < 0.001). Age > 70 years, male sex, higher Charlson/Deyo score ( > 1), elevated AFP at diagnosis, and higher T-stage were associated with worse survival (p value < 0.001). Conclusions: The approval of sorafenib has dramatically increased the use of chemotherapy for the treatment of advanced HCC and has resulted in a significant survival advantage." @default.
- W2947078595 created "2019-06-07" @default.
- W2947078595 creator A5005028498 @default.
- W2947078595 creator A5020594501 @default.
- W2947078595 creator A5020595766 @default.
- W2947078595 creator A5039047831 @default.
- W2947078595 creator A5042661172 @default.
- W2947078595 creator A5051948022 @default.
- W2947078595 creator A5078692994 @default.
- W2947078595 creator A5087450728 @default.
- W2947078595 date "2019-05-20" @default.
- W2947078595 modified "2023-09-28" @default.
- W2947078595 title "The impact of sorafenib on the treatment and survival of advanced hepatocellular carcinoma (HCC): Analysis of the National Cancer Database (NCDB) from 2004 to 2014." @default.
- W2947078595 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e15682" @default.
- W2947078595 hasPublicationYear "2019" @default.
- W2947078595 type Work @default.
- W2947078595 sameAs 2947078595 @default.
- W2947078595 citedByCount "0" @default.
- W2947078595 crossrefType "journal-article" @default.
- W2947078595 hasAuthorship W2947078595A5005028498 @default.
- W2947078595 hasAuthorship W2947078595A5020594501 @default.
- W2947078595 hasAuthorship W2947078595A5020595766 @default.
- W2947078595 hasAuthorship W2947078595A5039047831 @default.
- W2947078595 hasAuthorship W2947078595A5042661172 @default.
- W2947078595 hasAuthorship W2947078595A5051948022 @default.
- W2947078595 hasAuthorship W2947078595A5078692994 @default.
- W2947078595 hasAuthorship W2947078595A5087450728 @default.
- W2947078595 hasConcept C10515644 @default.
- W2947078595 hasConcept C121608353 @default.
- W2947078595 hasConcept C126322002 @default.
- W2947078595 hasConcept C143998085 @default.
- W2947078595 hasConcept C2778019345 @default.
- W2947078595 hasConcept C2778695046 @default.
- W2947078595 hasConcept C2993652001 @default.
- W2947078595 hasConcept C3019894029 @default.
- W2947078595 hasConcept C41008148 @default.
- W2947078595 hasConcept C71924100 @default.
- W2947078595 hasConcept C77088390 @default.
- W2947078595 hasConceptScore W2947078595C10515644 @default.
- W2947078595 hasConceptScore W2947078595C121608353 @default.
- W2947078595 hasConceptScore W2947078595C126322002 @default.
- W2947078595 hasConceptScore W2947078595C143998085 @default.
- W2947078595 hasConceptScore W2947078595C2778019345 @default.
- W2947078595 hasConceptScore W2947078595C2778695046 @default.
- W2947078595 hasConceptScore W2947078595C2993652001 @default.
- W2947078595 hasConceptScore W2947078595C3019894029 @default.
- W2947078595 hasConceptScore W2947078595C41008148 @default.
- W2947078595 hasConceptScore W2947078595C71924100 @default.
- W2947078595 hasConceptScore W2947078595C77088390 @default.
- W2947078595 hasLocation W29470785951 @default.
- W2947078595 hasOpenAccess W2947078595 @default.
- W2947078595 hasPrimaryLocation W29470785951 @default.
- W2947078595 isParatext "false" @default.
- W2947078595 isRetracted "false" @default.
- W2947078595 magId "2947078595" @default.
- W2947078595 workType "article" @default.